1. 42.2 16.7 years (range 9 – 88) and a mean duration of disease of 13.4 10 years (array 0.2 49) were enrolled. One hundred four individuals (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn’s disease. About the therapy: 62 individuals were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two individuals (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two individuals resulted positive for IgG against SARS-CoV-2 (0.77%). == Conclusions == In Oxprenolol HCl individuals with IBD, treatment with biologic drug does not represent Oxprenolol HCl a risk element for the SARS-CoV-2 illness. Keywords:Biologic therapy, IBD, SARS-CoV-2 == 1. Intro == The 20192020 Coronavirus disease (COVID-19) outbreak is an ongoing pandemic caused by a novel Coronavirus named Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), initially identified in Wuhan, China, where the 1st 5 individuals were hospitalized in Oxprenolol HCl December 2019[1]. At the end of January 2020, 7734 cases were confirmed in China, and 90 additional cases were reported from several European countries, such as Germany, France, and Finland[2]. The 1st Rabbit polyclonal to PPP1CB 16 Italian individuals infected with SARS-CoV-2 were authorized on February 21, 2020, in Codogno (Northern Italy). Since then, the virus offers spread throughout Italy. By July 19, 2020, over 244.000 individuals had been infected, of whom 35.000 died[3]. The median age of infected individuals was 64 years, and about one third of them presented with a severe disease which required admission to an intensive care unit in 5% of instances[3]. Factors associated with an aggressive course of the infection were: older age, male sex, concomitant co-morbidities (cardiomyopathy, hypertension, kidney failure, and chronic obstructive pulmonary disease), obesity, and active smoking[4],[5],[6],[7]. The part of air pollution is still under argument[8]. Individuals with inflammatory bowel disease (IBD) treated with biologics and/or immunosuppressant medicines are at higher risk for opportunistic infections[9]. A single-center study, carried out on 522 IBD individuals (both adult and pediatric subjects) living in an urban area with a high prevalence of COVID-19 illness, found no infected subjects either among those receiving immunosuppressant medicines (no.=22%) or biologics (no.=16%), or among those not treated with this class of compounds[10]. A multicenter study carried out from the Italian Group for Inflammatory Bowel Disease (IG-IBD) collected 79 instances of IBD individuals with the SARS-CoV-2 illness, ensuing in death in 6 individuals[11]. No IBD-specific features resulted associated with a poor end result (pneumonia, need for respiratory therapies, hospitalization, and death), whereas older age, male sex, and presence of co-morbidities were all significant predictors of a worse end result[11]. Despite the current pandemic, medical societies recommend keeping IBD individuals on their ongoing therapies, become these based on immunosuppressant or biologic medicines, as no evidence has yet incriminated these medicines like a potential element favoring and/or worsening the Coronavirus disease[12,13]. However, this indication needs to be backed by real-world data exploring the safety of these therapies during the current pandemic[14,15]. Two studies investigated the serum prevalence of SARS-CoV-2 illness in IBD individuals[16,17]. In the 1st one, 90 out of 103 individuals under current biologics therapy were investigated for the presence of IgG and or IgM against SARS-CoV-2 in the blood circulation: 19 of them resulted positive for IgG, IgM, or both (21%), suggesting that the majority of individuals had gone through an asymptomatic course of illness[16]. Of notice, this seroprevalence data was related to that experienced in a healthy control human population. At multivariate analysis, male sex was confirmed as protecting for the COVID-19 illness, while older age as more likely associated with a positive serological result[16]. Bert et al. tested, having a homemade ELISA assay for the detection of anti-SARS-CoV-2 specific IgG and IgA, 354 individuals with IBD from 3 different center treated with biologics: no significant variations were found in the IBD individuals when compared with a control human population of healthy subjects[17]. Only the presence of anosmia/ageusia was an Oxprenolol HCl independent predictor of IgG seropositivity at multivariate analysis (RR54.5, 95%CI 2.11434.9,p= 0.016)[17]. The aim of our study was to explore the risk of acquiring the SARS-CoV-2 illness and to evaluate the severity of the disease in individuals with IBD treated with biologics. == 2. Materials and methods == All individuals followed up in the IBD center in the Casa Sollievo della Sofferenza Study Hospital (San Giovanni Rotondo, Italy) who received at least one Oxprenolol HCl injection of a biologic drug for IBD from February 1st, 2020 on, were enrolled. Data on age, sex, IBD (type, period of disease, smoking habit, and ongoing treatments), and comorbidities according to the Charlson Comorbidity Index (CCI)[17]were collected. All individuals were accurately interviewed.